Switch to:

Corvus Pharmaceuticals EV-to-EBITDA

: -1.21 (As of Today)
View and export this data going back to 2016. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Corvus Pharmaceuticals's enterprise value is $55.93 Mil. Corvus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 was $-46.28 Mil. Therefore, Corvus Pharmaceuticals's EV-to-EBITDA for today is -1.21.

NAS:CRVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.14   Med: 0   Max: 0.81
Current: -1.21
-9.14
0.81

During the past 6 years, the highest EV-to-EBITDA of Corvus Pharmaceuticals was 0.81. The lowest was -9.14. And the median was 0.00.

NAS:CRVS's EV-to-EBITDA is ranked lower than
99.99% of the 275 Companies
in the Biotechnology industry.

( Industry Median: 29.35 vs. NAS:CRVS: -1.21 )

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2020-09-27), Corvus Pharmaceuticals's stock price is $4.01. Corvus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020 was $-1.55. Therefore, Corvus Pharmaceuticals's PE Ratio for today is .

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Corvus Pharmaceuticals EV-to-EBITDA Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Corvus Pharmaceuticals Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EV-to-EBITDA Premium Member Only 0.00 -4.52 -2.30 0.14 -1.61

Corvus Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.35 -0.11 -1.61 0.07 0.00
Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.

Corvus Pharmaceuticals EV-to-EBITDA Distribution

* The bar in red indicates where Corvus Pharmaceuticals's EV-to-EBITDA falls into.


Corvus Pharmaceuticals EV-to-EBITDA Calculation

Corvus Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=55.925/-46.275
=-1.21

Corvus Pharmaceuticals's current Enterprise Value is $55.93 Mil.
Corvus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 was -11.327 (Sep. 2019 ) + -11.255 (Dec. 2019 ) + -13.085 (Mar. 2020 ) + -10.608 (Jun. 2020 ) = $-46.28 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Corvus Pharmaceuticals  (NAS:CRVS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Corvus Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.01/-1.55
=

Corvus Pharmaceuticals's share price for today is $4.01.
Corvus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020 was -0.37 (Sep. 2019 ) + -0.38 (Dec. 2019 ) + -0.44 (Mar. 2020 ) + -0.36 (Jun. 2020 ) = $-1.55.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Corvus Pharmaceuticals EV-to-EBITDA Related Terms

Corvus Pharmaceuticals EV-to-EBITDA Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)